Canada: The Supreme Court On Screening Out Strikes Suits In Secondary Market Disclosure Class Actions: Theratechnologies Inc. v. 121851 Canada Inc.​

On April 17, 2015, the Supreme Court released its decision in TheratechnologiesInc. v. 121851 Canada Inc., 2015 SCC 18: ( addressing two important issues in secondary market disclosure actions. First, how strong a case does the plaintiff have to show to obtain leave to proceed with the action? Second, do concerns or questions posed by a government body amount to a material change that requires timely disclosure?

The action arose when Theratechnologies Inc. (Thera), a pharmaceutical company and reporting issuer based in Montréal, filed a new drug application with the United States Food and Drug Administration (FDA) for a flagship drug to reduce abdominal fat in HIV patients. Thera had carried out a number of clinical trials to test the efficacy and the safety of the drug, including a potential increased risk of diabetes. The results of these clinical trials had been published, and Thera had publicly stated that there were "no major safety concerns" in respect of diabetes.

In the course of its review, the FDA provided Thera with a briefing document that included questions about the drug's potential side effects. When these questions were published, investors became concerned about whether the drug in fact posed an increased risk of diabetes. Thera's stock price dropped by 58 percent in the space of two days. Three days after the publication of these questions, however, the Advisory Committee of the FDA unanimously voted in favour of the drug, which was ultimately approved. Thera's stock price promptly recovered.

The plaintiff, a numbered company that had sold its Thera shares for a loss following the publication of the FDA's briefing document, sought leave to launch a class action against Thera. The plaintiff alleged that Thera had breached its obligation to make timely disclosure of a material change, being the concerns expressed by the FDA.

Under s. 225.4 of the Québec Securities Act, a court will only grant leave for such an action if the court "deems that the action is in good faith and there is a reasonable possibility that it will be resolved in favour of the plaintiff". In that regard, the language of this provision is similar to the language in s. 138.8 of the Ontario Securities Act. As noted by the Supreme Court, s. 225.4 was added as a screening mechanism to discourage frivolous "strike" suits against issuers.

The motions judge, Blanchard J., found that the action had a reasonable possibility of success and granted leave for the action to proceed (2012 QCCS 699, Gascon J.A. (as he then was), writing for the Québec Court of Appeal (2013 QCCA 1256, g10fx) found that the "reasonable possibility of success" standard was higher than the usual merits standard required to certify a class action. He found that this higher threshold had been met, and affirmed the decision of the motions judge.

The Supreme Court, however, unanimously allowed the appeal. Reviewing the origin and purpose of s. 225.4, Justice Abella agreed that the provision created a higher standard than the general threshold applicable to class actions. In her view, "a case with a reasonable possibility of success requires the claimant to offer both a plausible analysis of the applicable legislative provisions, and some credible evidence in support of the claim" (para. 39). This exercise requires the court to review the plaintiff's evidence, but not to engage in a "full analysis of the evidence", which would amount to a "mini-trial".

Applying this approach, Justice Abella noted that the clinical trials giving rise to the the FDA's questions had been disclosed to shareholders as they had become available, as had been the possibility of side effects. She concluded that the publication of the FDA's questions materials did not amount to a material change in Thera's operations, capital or business that required disclosure. Instead, it was an event that was external to the issuer and its business. As a result, the Court found that the plaintiff had failed to point to any evidence of a material change requiring disclosure, and accordingly had not established a reasonable possibility of success.

The Thera decision provides some welcome clarity as to how strong a plaintiff's case must be to proceed with a secondary market disclosure action. In Green v. Canadian Imperial Bank of Commerce, for example, the Ontario Court of Appeal had suggested that the applicable standard was similar to the threshold applicable to class actions, although with the benefit of an evidentiary record (at paras. 81-88). The reporting issuers appealed Green to the Supreme Court and asked for a more robust review of the plaintiff's case in a leave application; the appeal was heard on February 9, 2015 but remains under reserve.

The Thera decision appears to have provided at least some of the higher degree of scrutiny asked for by the Green appellants. Justice Abella suggests that the threshold applicable to leave applications ought to be higher than that applicable to the certification of class actions. The result is arguably a modestly tighter screening mechanism than was previously endorsed by the Court of Appeal, which may make it more difficult for plaintiffs to bring secondary market disclosure actions. The Supreme Court's decision in Green is likely to adopt the approach set out in Thera. However, reporting issuers will no doubt be interested in how the Court actually applies that approach to the facts in Green, which may provide more useful guidance to litigants beyond ensuring that they use the same language in describing the test applicable to leave motions.

With respect to material changes, the Thera decision may come as a welcome development for issuers, as the Court ultimately sided with the issuer in determining that no disclosure was required. Thera's previous disclosure of the results of the clinical trials no doubt assisted it when the FDA raised concerns about those potential side effects. The facts in this case, however, were sympathetic to the issuer, as the FDA ultimately approved its drug application, vindicating Thera's statements about the results of the clinical studies and restoring its share price. The concern noted by the Court of Appeal (at paras. 164-70, 146-150), that there might be a reasonable case that Thera had not sufficiently disclosed the substance of the FDA's concerns when stating the results of the studies, might carry greater weight if an issuer's published studies turn out to be less well-received than the studies were in this case.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Osler, Hoskin & Harcourt LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Osler, Hoskin & Harcourt LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions